Continuation Treatment Protocol for Patients Who Participated in the Adagio TVP 1012/501 Clinical Trial

NCT01709461 | Unknown

• 1 other identifier: RD 06 - 12
• Study Type: observational
• Target: 12
• Locations: 1 country
• Sites: 1

Brief Summary

the purpose of the study is to extend the use of Rasagelin Mesylate 1mg per day by subjects who participated in the Adagio TVP 1012/501 according to form 4a for additional three years.

Conditions

Parkinson Disease

Eligibility Criteria

• Age: 30 Years - 80 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

subjects who took part in the TVP 1012/501 clinical trial and willing to contiue receiving Rasgiline Mesylate.

You may qualify if:

• subjects who are willing to contiue this treatment.
• subjects who took part in the TVP 1012/501 clinical trail.

You may not qualify if:

• subjects who didn't take part in the TVP 1012/501 clinical trail.

Sponsors & Collaborators

• Rabin Medical Center: lead

Study Sites (1)

Rabin Medical Center Beilinson Campus

Petach Tiqva, Central District, 49100, Israel

Location

MeSH Terms

Conditions

Parkinson Disease

Condition Hierarchy (Ancestors)

Parkinsonian Disorders; Basal Ganglia Diseases; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Movement Disorders; Synucleinopathies; Neurodegenerative Diseases

Central Study Contacts

Ruth Djaldetti, Professor

CONTACT

972-9378218/9; ruthdjal@clalit.org.il

Yaniv roditi, Msc

CONTACT

972-39236843; yar@clalit.org.il

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: October 14, 2012
• First Posted: October 18, 2012
• Study Start: October 1, 2012
• Last Updated: October 18, 2012

Record last verified: 2012-06

Locations

IL (1)